We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Read MoreHide Full Article
Key Takeaways
Pulse Biosciences shifts focus to nPulse AFib system after strong 150-patient European study results.
PLSE's nsPFA tech showed 100% procedural success at 6 months and 96% sustained success at 12 months.
Pulse Biosciences reallocates capital to support pivotal studies and future regulatory submissions.
Pulse Biosciences (PLSE - Free Report) recently announced a strategic shift aimed at accelerating the development and future commercialization of its nPulse Cardiac Catheter Ablation System. The initiative follows highly breakthrough clinical results from the company’s 150-patient European feasibility study, which showcased the strong potential of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology in treating Atrial Fibrillation (AFib).
Per management, data from more than 150 patients in Europe delivers a strong and conclusive signal, showing that the nPulse system has clear potential to transform clinical practice and improve treatment outcomes for millions. Advancing this program is a top priority, with capital allocation being adjusted to fully support the opportunity.
Paul LaViolette, CEO and Co-Chairman, added that the company is excited to dedicate additional resources to its catheter-based electrophysiology (EP) program, strengthening an initiative that has already demonstrated the potential to be both first-in-class and best-in-class.
Likely Trend of PLSE Stock Following the News
Shares of PLSE have lost 1.3% since the announcement on March 17. Over the past six months, shares of the company have climbed 23.9% against the industry’s 4.3% decline and the S&P 500’s 0.6% fall.
In the long run, PLSE’s sharp focus on the electrophysiology market could enhance its competitive positioning by channeling resources into a best-in-class catheter-based solution. This strategy increases its ability to capture share in the rapidly growing AFib treatment market while reinforcing its strengths in high-impact, scalable opportunities. The company’s disciplined capital allocation underscores confidence in its technological edge, particularly within its nPulse platform. Successful execution of pivotal trials and progress on regulatory milestones could serve as critical catalysts for sustained performance. If upcoming studies validate early clinical outcomes, the nPulse platform has the potential to transform AFib treatment and position Pulse Biosciences for long-term growth within the global electrophysiology landscape.
PLSE currently has a market capitalization of $1.45 billion.
Image Source: Zacks Investment Research
More on the Strategic Alignment
According to the data presented at the 31st Annual AF Symposium, the system achieved 100% procedural success at six months among evaluable patients and delivered a remarkable 96% sustained success rate at 12 months, highlighting durable pulmonary vein isolation — an outcome that stands out in a field where recurrence rates of 20-25% are expected.
Beyond effectiveness, the procedure demonstrated strong efficiency metrics, including an average total procedure time of just 65 minutes and a reduced left atrial dwell time, along with minimal fluoroscopy exposure. The system also showed a favorable safety profile, with only a 1.3% rate of serious adverse events, reinforcing its potential to emerge as a best-in-class solution in the growing electrophysiology market.
To capitalize on these strong clinical outcomes, Pulse Biosciences is now concentrating the majority of its research, development and clinical investment on the cardiac catheter program, particularly the upcoming pivotal IDE study in the United States and Europe that will support future regulatory submissions. At the same time, the company is recalibrating other programs to free up capital for this high-value opportunity.
While the surgical clamp program will continue, near-term market development spending in cardiac surgery will be reduced. Operations for the percutaneous soft-tissue ablation system have been streamlined, with a focused strategy centered on advancing the Vybrance Percutaneous Electrode System toward an on-label indication for benign thyroid nodules, generating real-world data and validating reimbursement pathways.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the electrophysiology ablation market is valued at $8.01 billion in 2026 and is expected to witness a CAGR of 11.8% through 2035.
Factors like the rising use of minimal invasive catheter-based ablation, increasing implementation of AI-powered 3D mapping and navigation solutions to enhance precision and increased application of electrophysiology ablation in the management of atrial fibrillation are boosting the market’s growth.
Other News
Pulse Biosciences recently reported promising long-term results from its first-in-human study of the nPulse Vybrance system for treating benign thyroid nodules using nsPFA technology. Data presented at the North American Society for Interventional Thyroidology 2026 meeting showed a sustained average nodule volume reduction of 74% over 15-22 months, with no regrowth or serious adverse events. Patient satisfaction was high, with 100% cosmetic satisfaction reported and 95% overall satisfaction. The treatment demonstrated continued improvement over time without fibrosis, highlighting its durability and safety.
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Key Takeaways
Pulse Biosciences (PLSE - Free Report) recently announced a strategic shift aimed at accelerating the development and future commercialization of its nPulse Cardiac Catheter Ablation System. The initiative follows highly breakthrough clinical results from the company’s 150-patient European feasibility study, which showcased the strong potential of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology in treating Atrial Fibrillation (AFib).
Per management, data from more than 150 patients in Europe delivers a strong and conclusive signal, showing that the nPulse system has clear potential to transform clinical practice and improve treatment outcomes for millions. Advancing this program is a top priority, with capital allocation being adjusted to fully support the opportunity.
Paul LaViolette, CEO and Co-Chairman, added that the company is excited to dedicate additional resources to its catheter-based electrophysiology (EP) program, strengthening an initiative that has already demonstrated the potential to be both first-in-class and best-in-class.
Likely Trend of PLSE Stock Following the News
Shares of PLSE have lost 1.3% since the announcement on March 17. Over the past six months, shares of the company have climbed 23.9% against the industry’s 4.3% decline and the S&P 500’s 0.6% fall.
In the long run, PLSE’s sharp focus on the electrophysiology market could enhance its competitive positioning by channeling resources into a best-in-class catheter-based solution. This strategy increases its ability to capture share in the rapidly growing AFib treatment market while reinforcing its strengths in high-impact, scalable opportunities. The company’s disciplined capital allocation underscores confidence in its technological edge, particularly within its nPulse platform. Successful execution of pivotal trials and progress on regulatory milestones could serve as critical catalysts for sustained performance. If upcoming studies validate early clinical outcomes, the nPulse platform has the potential to transform AFib treatment and position Pulse Biosciences for long-term growth within the global electrophysiology landscape.
PLSE currently has a market capitalization of $1.45 billion.
Image Source: Zacks Investment Research
More on the Strategic Alignment
According to the data presented at the 31st Annual AF Symposium, the system achieved 100% procedural success at six months among evaluable patients and delivered a remarkable 96% sustained success rate at 12 months, highlighting durable pulmonary vein isolation — an outcome that stands out in a field where recurrence rates of 20-25% are expected.
Beyond effectiveness, the procedure demonstrated strong efficiency metrics, including an average total procedure time of just 65 minutes and a reduced left atrial dwell time, along with minimal fluoroscopy exposure. The system also showed a favorable safety profile, with only a 1.3% rate of serious adverse events, reinforcing its potential to emerge as a best-in-class solution in the growing electrophysiology market.
To capitalize on these strong clinical outcomes, Pulse Biosciences is now concentrating the majority of its research, development and clinical investment on the cardiac catheter program, particularly the upcoming pivotal IDE study in the United States and Europe that will support future regulatory submissions. At the same time, the company is recalibrating other programs to free up capital for this high-value opportunity.
While the surgical clamp program will continue, near-term market development spending in cardiac surgery will be reduced. Operations for the percutaneous soft-tissue ablation system have been streamlined, with a focused strategy centered on advancing the Vybrance Percutaneous Electrode System toward an on-label indication for benign thyroid nodules, generating real-world data and validating reimbursement pathways.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the electrophysiology ablation market is valued at $8.01 billion in 2026 and is expected to witness a CAGR of 11.8% through 2035.
Factors like the rising use of minimal invasive catheter-based ablation, increasing implementation of AI-powered 3D mapping and navigation solutions to enhance precision and increased application of electrophysiology ablation in the management of atrial fibrillation are boosting the market’s growth.
Other News
Pulse Biosciences recently reported promising long-term results from its first-in-human study of the nPulse Vybrance system for treating benign thyroid nodules using nsPFA technology. Data presented at the North American Society for Interventional Thyroidology 2026 meeting showed a sustained average nodule volume reduction of 74% over 15-22 months, with no regrowth or serious adverse events. Patient satisfaction was high, with 100% cosmetic satisfaction reported and 95% overall satisfaction. The treatment demonstrated continued improvement over time without fibrosis, highlighting its durability and safety.
Pulse Biosciences, Inc Price
Pulse Biosciences, Inc price | Pulse Biosciences, Inc Quote
PLSE’s Zacks Rank & Other Key Picks
Currently, PLSE has a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Phibro Animal Health (PAHC - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) .
Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.
Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.